Exhibit
31.2





CERTIFICATION
PURSUANT TO SECURITIES EXCHANGE ACT RULES 13a-14(a) and 15d-14(a)


AS
ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002





I,
Sanding Tao, certify that:




1. I have
reviewed this Quarterly Report on Form 10-Q of Huifeng Bio-Pharmaceutical
Technology Inc.;




2. Based
on my knowledge, this Quarterly Report does not contain any untrue statement of
a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were
made, not misleading with respect to the period covered by this Quarterly
Report;




3. Based
on my knowledge, the financial statements, and other financial information
included in this Quarterly Report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this Quarterly Report;




4. The
registrant’s other certifying officer(s) and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and
have:




(a)         designed
such disclosure controls and procedures, or caused such disclosure controls and
procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the
period in which this Quarterly Report is being prepared;




(b)         designed
such internal control over financial reporting, or caused such internal control
over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements, for external purposes in accordance with
generally accepted accounting principles;




(c)         evaluated
the effectiveness of the registrant’s disclosure controls and procedures and
presented in this Quarterly Report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by
this Quarterly Report based on such evaluation; and




(d)         disclosed
in this Quarterly Report any change in the registrant’s internal control over
financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and




5. The
registrant’s other certifying officer(s) and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of
directors (or persons performing the equivalent functions):




(a)         all
significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to
adversely affect the registrant’s ability to record, process, summarize and
report financial information; and




(b)         any
fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant’s internal control over financial
reporting.




Date: May
17, 2010





By:
                /s/
      Sanding TaoSanding
      Tao
                  Principal
      Accounting and Financial
Officer